Matrilysin Expression in Different Stages of Colorectal Tumors
MMP7
1 other identifier
observational
38
1 country
1
Brief Summary
Matrix metalloproteinases (MMPs) have been shown to be involved in cancer biology. Significant expression of MMP-7 (matrilysin) in colorectal cancer is mainly associated with metastatic disease even though it is expressed in most tumor states. Our purpose is to analyse MMP-7 in bowel and lymph nodes of different tumor stages and to evaluate its expression as a potential biomarker of cancer disease in patients surgically treated for benign and malignant colorectal tumors. Tumoral tissue, lymph nodes and serum samples from recruited Patients plus serum samples from healthy volunteers are analysed for matrilysin expression by histology, immunohistochemistry, ELISA and Western blotting. If Matrilysin increases with increasing dysplasia and cancer disease stage in tumor tissue as well as in the regional lymph nodes it might be used as a complement in investigating suspected locally advanced cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 31, 2012
CompletedFirst Posted
Study publicly available on registry
April 4, 2012
CompletedApril 4, 2012
March 1, 2012
3 years
March 31, 2012
April 3, 2012
Conditions
Keywords
Study Arms (4)
healthy volunteers
healthy subjects not affected by benign or malignant colonic disease
benign colonic tumor patients
patients affected by benign colonic tumor such as adenoma
cancer patient I-II stage
Patients affected by colonic cancer in I-II stage
cancer patients III-IV stage
Patients affected by colonic cancer in III-IV stage
Interventions
standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
Eligibility Criteria
patients affected by colorectal neoplasm admitted to our department of surgery
You may qualify if:
- benign colonic neoplasm not suitable for endoscopic treatment,
- malignant colonic neoplasm with indication to primary surgical treatment
You may not qualify if:
- neo-adjuvant radiotherapy,
- chemo-radiotherapy,
- language problems and withdrawal of consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Departement of Surgery Pietro Valdoni
Rome, 00161, Italy
Related Publications (1)
Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer. 1995 Mar 15;75(6 Suppl):1516-9. doi: 10.1002/1097-0142(19950315)75:6+3.0.co;2-7.
PMID: 7889484BACKGROUND
Biospecimen
normal mucosa, cancer tissue, lymph nodes and serum from cancer patients serum from healty volunteers
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrea Polistena, MD
Department of Surgery Pietro Valdoni, University La Sapienza Rome
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD specialist in General Surgery
Study Record Dates
First Submitted
March 31, 2012
First Posted
April 4, 2012
Study Start
September 1, 2005
Primary Completion
September 1, 2008
Study Completion
February 1, 2012
Last Updated
April 4, 2012
Record last verified: 2012-03